Obagi Medical and Platinum Dermatology Partners Announce Collaboration in the ALOHA Program to Drive Real-World Evidence for Obagi® saypha® MagIQ(TM)
MWN-AI** Summary
Obagi Medical, a prominent innovator in physician-dispensed skincare, has partnered with Platinum Dermatology Partners to launch the ALOHA Program aimed at generating real-world evidence for Obagi® saypha® MagIQ™. This collaboration is designed to translate the clinical safety and efficacy proven in FDA pivotal trials into practical applications across various dermatological practices.
Michael Pennington, CEO and co-founder of Platinum Dermatology Partners, emphasized the alignment of their clinical expertise with Obagi's innovative approach to product development. He noted that their injectors' everyday experiences with patients would be invaluable in evaluating the product's performance in real-world scenarios. The ALOHA Program aims to enhance patient satisfaction and strengthen the connection between patients and their healthcare providers through hands-on experience with Obagi's offerings.
The initiative not only includes a real-world clinical component but also a structured evaluation process across multiple Platinum locations. Initial findings from this collaboration are scheduled to be presented at the upcoming Platinum Summit in Dallas, with additional presentations planned for industry conferences to showcase the product's benefits and implications.
Drew Fine, U.S. General Manager of the Professional Channel at Obagi, articulated that this partnership with Platinum demonstrates a commitment to launching their new injectable with strong clinical backing and integrated patient outcomes. The Obagi® saypha® MagIQ™ employs cutting-edge MACRO Core Technology, promising natural-looking results and superior performance metrics.
Overall, this collaboration represents a strategic step in elevating standards in aesthetic dermatology, highlighting Obagi's dedication to innovation in skincare and injectable aesthetics through the power of real-world evidence.
MWN-AI** Analysis
The recent collaboration between Obagi Medical and Platinum Dermatology Partners, announced through the ALOHA Program, presents a significant opportunity to enhance market strategies and drive brand awareness for Obagi’s latest product, saypha® MagIQ™. This partnership is strategic, leveraging Platinum Dermatology’s extensive clinical expertise and real-world patient engagement to generate robust evidence supporting the safety and efficacy of Obagi's innovative hyaluronic acid injectable.
Investors should take note of the implications this collaboration could have on Obagi Medical’s market positioning. By aligning with a reputable network like Platinum, which encompasses over 120 locations and nearly 400 providers, Obagi can facilitate crucial data collection that not only validates its product's clinical performance but also solidifies its reputation in the competitive medical aesthetics market. This move is likely to enhance patient trust and satisfaction, two critical factors in aesthetic dermatology.
Moreover, the emphasis on presenting findings at key industry conferences and initiatives to raise awareness within the community underscores a comprehensive approach to fostering brand credibility. The structured evaluation process and standardized data capture from multiple practices will provide compelling insights likely to influence both patient and provider perceptions favorably.
Considering Obagi’s growth trajectory, evidenced by its status as the fastest-growing professional skincare brand in the U.S. as of 2024, the ALOHA Program could serve as a catalyst for sustained market expansion, particularly as consumer interest in minimally invasive aesthetic solutions continues to rise.
For investors, it may be wise to watch for initial data releases and market responses to the ALOHA initiative, as these could significantly impact Obagi's share price. The promising nature of saypha® MagIQ™, combined with strong clinical validation, positions Obagi Medical favorably within a burgeoning industry, suggesting potential for long-term growth and profitability.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
NEW YORK and DALLAS, Jan. 26, 2026 (GLOBE NEWSWIRE) -- Obagi Medical, a leading innovator in physician-dispensed skincare and aesthetic solutions and part of Waldencast plc (NASDAQ: WALD) (“Waldencast” or the “Company”), today announced Platinum Dermatology Partners as the launch partner for the Aesthetics Leadership with Obagi’s Hyaluronic Acid (ALOHA) Program.
Platinum will help generate real-world data to translate the clinical safety and efficacy demonstrated in FDA pivotal trials into everyday practice across multiple trials and evaluation programs.
"This partnership with Obagi makes sense for us. They're taking a different approach to product development, and we have the clinical expertise to help them understand how trial data performs in real-world practice,” said Michael Pennington, Chief Executive Officer and Co-founder of Platinum Dermatology Partners. “Our injectors treat patients every day. That experience matters. This is the kind of work we should be doing. Obagi is thinking differently about product development, and that aligns with how we approach patient care. It's about raising the standard for aesthetic dermatology.”
The ALOHA Real-World Program is designed to give Platinum providers hands-on experience with Obagi saypha MagIQ while evaluating complete Obagi protocols. This approach aims to drive patient satisfaction and strengthen relationships between patients and their Platinum providers. The program includes a real-world clinical initiative supplemented by a structured evaluation process across multiple Platinum practices and providers, with standardized data capture.
Platinum will present initial findings at this September's annual Platinum Summit in Dallas, highlighting the benefits of the new product and its protocols within the Platinum network. Results will also be presented at key industry conferences to demonstrate the real-world impact of introducing this innovative injectable across Platinum’s practices.
“Partnering with Platinum is a clear statement of our intent to launch this new injectable on a foundation of robust clinical evidence, education, and integrated patient outcomes,” said Drew Fine, U.S. General Manager, Professional Channel. “The ALOHA program will serve as a platform for a differentiated launch strategy and underscore Obagi Medical’s commitment to delivering innovative products across every facet of skincare and now injectable aesthetics.”
Obagi® saypha® MagIQ™, developed by Croma-Pharma GmbH, utilizes proprietary MACRO Core Technology to create a stable three-dimensional hyaluronic acid matrix. This technology is designed to deliver natural-looking results with category-leading performance, including high usable HA content upon injection, consistent gel distribution, and a predictable injection force and swelling profile1.
For more information about ALOHA, visit https://obagi-professional.com/
About Obagi Medical
Obagi Medical is an industry-leading, advanced skincare line rooted in research and skin biology, with a legacy of 35+ years of experience. Initially known for its leadership in the treatment of hyperpigmentation with the Obagi Nu-Derm® System, Obagi Medical products are designed to address a variety of skin concerns, including premature aging, photodamage, skin discoloration, acne, and sun damage. As the fastest-growing professional skincare brand in the U.S. in 2024,2 Obagi Medical empowers individuals to achieve healthy, beautiful skin. More information about Obagi Medical is available on the brand's website, https://www.obagi.com.
About Platinum Dermatology Partners
Headquartered in Dallas, Texas, Platinum Dermatology Partners exists to empower the practice of exceptional dermatology through its vast resources and differentiated culture. Today, Platinum spans over 120 locations and nearly 400 providers across Arizona, California, Florida, Nevada, and Texas. Through Platinum’s differentiated, physician-driven model, the company creates a collaborative group practice setting with a focus on partnering with the most reputable physicians and providers seeking to elevate not only the patient care delivered but also benefit the specialty of dermatology at large. For more information about Platinum Dermatology Partners, please visit www.platinumderm.com.
About Waldencast plc
Founded by Michel Brousset and Hind Sebti, Waldencast’s ambition is to build a global best-in-class beauty and wellness operating platform by developing, acquiring, accelerating, and scaling conscious, high-growth purpose-driven brands. Waldencast’s vision is fundamentally underpinned by its brand-led business model that ensures proximity to its customers, business agility, and market responsiveness, while maintaining each brand’s distinct DNA. The first step in realizing its vision was the Business Combination. As part of the Waldencast platform, its brands will benefit from the operational scale of a multi-brand platform; the expertise in managing global beauty brands at scale; a balanced portfolio to mitigate category fluctuations; asset light efficiency; and the market responsiveness and speed of entrepreneurial indie brands. For more information please visit: https://ir.waldencast.com.
Media Contact:
obagi@behrmancesa.com
Source: Waldencast plc
- Puljic A, Frank K, Cohen J, Otto K, Mayr J, Hugh-Bloch A, Kuroki-Hasenöhrl, D. A Scientific Framework for Comparing Hyaluronic Acid Filler Crosslinking Technologies. Gels. 2025; 11(7):487
- *Among the Top 10 Professional Skin Care Brands in the U.S., According to Kline’s 2024 Global Professional Skin Care Series (China, Europe and the U.S.)
FAQ**
How does the partnership between Platinum Dermatology Partners and Obagi Medical enhance the clinical safety and efficacy of Waldencast Acquisition Corp. WALD's new injectable skincare products in real-world settings?
In what ways could the ALOHA Program's introduction in Dallas impact patient satisfaction compared to similar initiatives in New York?
What strategies will Waldencast Acquisition Corp. WALD implement to leverage the initial findings presented at the Platinum Summit in Dallas to optimize its market approach in cities like New York?
How might the competitive dynamics of the professional skincare market, particularly in Dallas and New York, influence Waldencast Acquisition Corp. WALD's growth and innovation strategies in the coming years?
**MWN-AI FAQ is based on asking OpenAI questions about Waldencast Acquisition Corp. (NASDAQ: WALD).
NASDAQ: WALD
WALD Trading
-4.69% G/L:
$1.525 Last:
13,064 Volume:
$1.51 Open:
